Literature DB >> 25856382

High Rate of Cardiac Abnormalities in a Postmortem Analysis of Patients Suffering From Liver Cirrhosis.

Malte H Wehmeyer1, Anika J Heuer, Daniel Benten, Klaus Püschel, Karsten Sydow, Ansgar W Lohse, Stefan Lüth.   

Abstract

BACKGROUND: Cirrhotic cardiomyopathy is a recently defined cardiac disorder in patients with end-stage liver disease. The frequency and exact manifestations of cardiac changes in liver cirrhosis is unknown. GOALS: We aim to describe cardiac changes in a large autopsy study of patients with liver cirrhosis. STUDY: Postmortem data from 895 individuals with liver cirrhosis of different origin autopsied from 1995 to 2010 were analyzed. A total of 236 patients were excluded, mostly due to an advanced age above 70 years. The remaining 659 patients were assigned to 4 subgroups according to the etiology of cirrhosis: alcoholic cirrhosis (57.4%), nonalcoholic steatohepatitis (4.2%), viral hepatitis (9.3%), and cryptogenic cirrhosis (29.1%). Predefined clinical and cardiac parameters were assessed in these groups and compared by univariate and multivariate analyses to an age-matched and sex-matched control group including 40 deceased patients without evidence of chronic liver disease.
RESULTS: A critical heart weight (24%, P=0.024), hypertrophy of the right ventricle (24%, P<0.001), and dilatation of the right ventricle (36%, P=0.040) were significantly more frequent in the cirrhosis group compared with noncirrhotic controls. Cirrhosis patients had a greater risk for high-grade coronary sclerosis (30%, P=0.019). The etiology of cirrhosis was independently associated with hypertrophy and dilatation of the right ventricle, with nonalcoholic steatohepatitis patients being at the highest risk.
CONCLUSION: Our results demonstrate a high rate of right-ventricular abnormalities and coronary sclerosis in individuals suffering from liver cirrhosis regardless of the etiology of cirrhosis.

Entities:  

Mesh:

Year:  2015        PMID: 25856382     DOI: 10.1097/MCG.0000000000000323

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Impact of Cirrhotic Cardiomyopathy Diagnosed According to Different Criteria on Patients with Cirrhosis Awaiting Liver Transplantation: A Retrospective Cohort Study.

Authors:  Achintya D Singh; Andrew Ford; Ruishen Lyu; Habib Layoun; Serge C Harb; Maan Fares; William D Carey
Journal:  Dig Dis Sci       Date:  2022-02-12       Impact factor: 3.487

2.  Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis.

Authors:  Miaomiao Li; Zeqi Guo; Dan Zhang; Xiangbo Xu; Fernando Gomes Romeiro; Andrea Mancuso; Jingqiao Zhang; Ruirui Feng; Xinmiao Zhou; Cen Hong; Xingshun Qi
Journal:  Gastroenterol Res Pract       Date:  2020-09-24       Impact factor: 2.260

3.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

4.  Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis.

Authors:  Li-Kun Wang; Xiao-Fei An; Xue-Liang Wu; Su-Mei Zhang; Rui-Min Yang; Chao Han; Jie-Lin Yang; Yi-Cheng Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

Review 5.  Chinese guidelines on the management of liver cirrhosis (abbreviated version).

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Jing-Hang Xu; Ying Han; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; En-Qiang Ling-Hu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

Review 6.  Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart.

Authors:  Revanth Kalluru; Sai Gadde; Rahul Chikatimalla; Thejaswi Dasaradhan; Jancy Koneti; Swathi Priya Cherukuri
Journal:  Cureus       Date:  2022-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.